Cover Image
市場調查報告書

乾眼症症候群(DES)- 美國的醫藥品的預測與市場分析

Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 281778
出版日期 內容資訊 英文 196 Pages
訂單完成後即時交付
價格
Back to Top
乾眼症症候群(DES)- 美國的醫藥品的預測與市場分析 Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024
出版日期: 2015年11月05日 內容資訊: 英文 196 Pages
簡介

本報告提供美國的乾眼症症候群(DES)治療藥調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊,主要藥物的銷售額預測,主要活動的影響分析,推動市場要素、阻礙因素等驗證結果,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因學
    • 病理學
  • 分類
  • 徵兆
  • 預後
  • 生活品質(QoL)

第4章 疾病的管理

  • 概要
    • 診斷
    • 治療的指南
    • 治療概要
  • 美國

第5章 競爭環境

  • 概要
  • 產品簡介
    • Restasis (cyclosporine)
    • Diquas (diquafosol tetrasodium)
    • Mucosta (rebamipide的2%眼科用懸浮液劑)
    • Ikervis (cyclosporine)
    • 人工淚液
    • 其他

第6章 未滿足需求和機會

  • 概要
  • 新的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 改良的診斷工具
  • 為了得到法規當局認證的恰當臨床實驗設計
  • 投藥的簡略化
  • 改善耐用性及遵守的患者教育
  • 改善醫生及患者對疾病理解

第7章 開發平台評估

  • 概要
  • 臨床實驗的製圖
  • 臨床實驗階段的潛力藥物
  • 開發初期階段的有希望的藥物
  • 開發中的其他藥劑

第8章 市場預測

  • 美國
    • 預測
    • 主要的活動
    • 推動因素、障礙

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC296CFR

Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis' recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.

GlobalData estimates that DES drug sales in the US reached $1.3 billion during 2014, making it the largest market within the 9MM. After an initial period of minimal growth, GlobalData estimates that the DES market will undergo a period of steady growth from 2016 and beyond, but this growth will begin to wane slightly towards the end of the forecast period. This growth is mainly attributed to the expected introduction of the highly anticipated pipeline DES drug, lifitegrast in late 2016, and additional pipeline products in 2018. This expansion of treatment options for DES patients will have the added effect of increasing overall treatment rates in the US.

Scope

  • Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US DES market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for DES.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Disease Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Clinical Practice
  • 4.2. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles
    • 5.2.1. Restasis (cyclosporine)
    • 5.2.2. Diquas (diquafosol tetrasodium)
    • 5.2.3. Mucosta ophthalmic solution (rebamipide)
    • 5.2.4. Ikervis (cyclosporine)
    • 5.2.5. Artificial Tears
    • 5.2.6. Other therapies

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. New Therapies for DES
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Diagnostic Tools
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Appropriate Clinical Trial Design to Secure Regulatory Approval
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Simplified Dosing
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Patient Education to Improve Tolerance and Compliance
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Physician and Patient Disease Awareness
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trial Design for DES
    • 7.2.2. Ora for DES Drug Development
  • 7.3. Promising Drugs in Clinical Development
    • 7.3.1. Lifitegrast
    • 7.3.2. Tavilermide
    • 7.3.3. Visomitin
    • 7.3.4. RGN-259
    • 7.3.5. Cis-UCA
    • 7.3.6. SI-614
  • 7.4. Promising Drugs in Early-Stage Development
    • 7.4.1. KPI-121
    • 7.4.2. Ozagrel
    • 7.4.3. P-321
    • 7.4.4. Dextenza (OTX-DP)
  • 7.5. Other Drugs in Development

8. Market Outlook

  • 8.1. US
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed DES Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Launch Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Dry Eye Syndrome
  • Table 2: National and International Treatment Guidelines for DES
  • Table 3: Country Profile - US
  • Table 4: Leading Treatments for DES, 2015
  • Table 5: Product Profile - Restasis
  • Table 6: Restasis SWOT Analysis, 2015
  • Table 7: Global Sales Forecast ($m) for Restasis, 2014-2024
  • Table 8: Product Profile - Diquas
  • Table 9: Diquas SWOT Analysis, 2015
  • Table 10: Global Sales Forecast ($m) for Diquas, 2014-2024
  • Table 11: Product Profile - Mucosta
  • Table 12: Mucosta SWOT Analysis, 2015
  • Table 13: Global Sales Forecast ($m) for Mucosta, 2014-2024
  • Table 14: Product Profile - Ikervis
  • Table 15: Ikervis SWOT Analysis, 2015
  • Table 16: Global Sales Forecast ($m) for Ikervis, 2014-2024
  • Table 17: Artificial Tears SWOT Analysis, 2015
  • Table 18: Global Sales Forecast ($m) for Artificial Tears, 2014-2024
  • Table 19: Unmet Needs and Opportunities in DES
  • Table 20: Promising Drugs in Clinical Development for Dry Eye Syndrome, 2015
  • Table 21: Comparison of Drugs in Development for Dry Eye Syndrome, 2015
  • Table 22: Product Profile - Lifitegrast
  • Table 23: SWOT Analysis - Lifitegrast, 2015
  • Table 24: Global Sales Forecast ($m) for Lifitegrast, 2014-2024
  • Table 25: Product Profile - Tavilermide
  • Table 26: SWOT Analysis - tavilermide, 2015
  • Table 27: Global Sales Forecast ($m) for tavilermide, 2014-2024
  • Table 28: Product Profile - Visomitin
  • Table 29: SWOT Analysis - Visomitin, 2015
  • Table 30: Global Sales Forecast ($m) for Visomitin, 2014-2024
  • Table 31: Product Profile - RGN-259
  • Table 32: SWOT Analysis - RGN-259, 2015
  • Table 33: Global Sales Forecast ($m) for RGN-259, 2014-2024
  • Table 34: Product Profile - Cis-UCA
  • Table 35: Product Profile - SI-614
  • Table 36: Drugs in Development, 2015
  • Table 37: US Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 38: Key Events That Will Impact Sales for DES Therapies in the US, 2014-2024
  • Table 39: DES Market - Drivers and Barriers in the US, 2014-2024
  • Table 40: Key Launch Dates
  • Table 41: Surveyed High-prescribing Physicians, by Country

List of Figures

  • Figure 1: Dry Eye Syndrome - Disease Etiology
  • Figure 2: The Tear Film in normal and dry eye
  • Figure 3: Varied Symptoms of Dry Eye Syndrome
  • Figure 4: Dry Eye Syndrome Therapeutics - Phase II and II/III Clinical Trials in the 9MM, 2015
  • Figure 5: DES Phase II/Phase III Pipeline, 2015
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in DES, 2014-2024
  • Figure 7: Clinical and Commercial Positioning of lifitegrast
  • Figure 8: Clinical and Commercial Positioning of tavilermide
  • Figure 9: Clinical and Commercial Positioning of Visomitin
  • Figure 10: Clinical and Commercial Positioning of RGN-259
  • Figure 11: Drug Sales for DES Therapies in the US, 2014 and 2024
Back to Top